PacBio Hints at Low-Cost Future Instruments; Aims to Capture 10 Percent of NGS Market
January 11, 2011
PacBio Hints at Low-Cost Future Instruments; Aims to Capture 10 Percent of NGS Market
"Over time, there is no reason why we can't build an instrument that costs $50,000, $100,000, $300,000, so we have got a tremendous portfolio opportunity ahead of us over time," a PacBio official said.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- PacBio Books 7 RS Systems in Q3, Delays Launch of C2 Chemistry, Launches 'Customer Advocacy' Group
November 1, 2011 / In Sequence - PacBio Looks to Raise up to $200M in IPO; Reports $15M Order Backlog
August 24, 2010 / In Sequence - PacBio Sequencing to Support 100K Genome Project
January 8, 2013 / GenomeWeb Daily News - PacBio Books Four Systems in Q3; Plans Q4 Chemistry Upgrade to Enable Longer Average Read Length
October 29, 2012 / In Sequence - PacBio Books One New Instrument in Q2; Will Focus on Epigenetic and Assembly Applications
July 31, 2012 / In Sequence